Free tool
FAERS Monitor: Cligavyx
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 210063 or its brand name (Cligavyx, Fulvestrant). Reports on generic versions are filed under their own applications.
Reports
17,216
Serious
15,760
92% of reports
Hospitalization
4,473
Death reported
2,840
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- malignant neoplasm progression2,842
- fatigue1,865
- neutropenia1,718
- nausea1,598
- metastases to bone1,493
- death1,411
- diarrhoea1,408
- breast cancer metastatic1,259
- metastases to liver1,226
- neoplasm progression986
- asthenia967
- vomiting917
- pain902
- dyspnoea871
- anaemia839
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 15 |
| 2006 | 9 |
| 2007 | 6 |
| 2008 | 20 |
| 2009 | 9 |
| 2010 | 8 |
| 2011 | 47 |
| 2012 | 40 |
| 2013 | 28 |
| 2014 | 35 |
| 2015 | 120 |
| 2016 | 254 |
| 2017 | 483 |
| 2018 | 699 |
| 2019 | 1,157 |
| 2020 | 2,013 |
| 2021 | 2,071 |
| 2022 | 2,058 |
| 2023 | 2,861 |
| 2024 | 1,970 |
| 2025 | 2,074 |
| 2026 | 1,237 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,036,943 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| breast cancer metastaticSignal | 1,259 | 162.2 | 153.2 | 178,007 |
| metastases to boneSignal | 1,493 | 122.1 | 116.1 | 163,094 |
| metastases to liverSignal | 1,226 | 91.6 | 86.6 | 102,184 |
| neoplasm progressionSignal | 986 | 35.6 | 33.5 | 32,269 |
| malignant neoplasm progressionSignal | 2,842 | 34.8 | 33.7 | 91,241 |
| neutropeniaSignal | 1,718 | 15.6 | 14.9 | 23,351 |
| anaemiaSignal | 839 | 5.4 | 5.0 | 3,013 |
| astheniaSignal | 967 | 3.1 | 3.0 | 1,437 |
| fatigueSignal | 1,865 | 2.9 | 2.8 | 2,456 |
| diarrhoeaSignal | 1,408 | 2.7 | 2.5 | 1,510 |
| nauseaSignal | 1,598 | 2.5 | 2.4 | 1,448 |
| vomitingSignal | 917 | 2.4 | 2.2 | 752 |
| deathSignal | 1,411 | 2.0 | 1.9 | 736 |
| dyspnoea | 871 | 1.9 | 1.8 | 368 |
| pain | 902 | 1.8 | 1.7 | 326 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.